Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus

Franz J. Zemp, Brienne A. McKenzie, Xueqing Lun, Karlyne M. Reilly, Douglas McFadden, V. Wee Yong, Peter A. Forsyth

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Oncolytic virus therapy is being evaluated in clinical trials for human glioma. While it is widely assumed that the immune response of the patient to the virus infection limits the utility of the therapy, investigations into the specific cell type(s) involved in this response have been performed using nonspecific pharmacologic inhibitors or allogeneic models with compromised immunity. To identify the immune cells that participate in clearing an oncolytic infection in glioma, we used flow cytometry and immunohistochemistry to immunophenotype an orthotopic glioma model in immunocompetent mice after Myxoma virus (MYXV) administration. These studies revealed a large resident microglia and macrophage population in untreated tumors, and robust monocyte, T-, and NK cell in filtration 3 days after MYXV infection. To determine the role on the clinical utility of MYXV therapy for glioma, we used a combination of knockout mouse strains and specific immunocyte ablation techniques. Collectively, our experiments identify an important role for tumor-resident myeloid cells and overlapping roles for recruited NK and T cells in the clearance and efficacy of oncolytic MYXV from gliomas. Using a cyclophosphamide regimen to achieve lymphoablation prior and during MYXV treatment, we prevented treatment-induced peripheral immunocyte recruitment and, surprisingly, largely ablated the tumor-resident macrophage population. Virotherapy of cyclophosphamide-treated animals resulted in sustained viral infection within the glioma as well as a substantial survival advantage. This study demonstrates that resistance to MYXV virotherapy in syngeneic glioma models involves a multifaceted cellular immune response that can be overcome with cyclophosphamide-mediated lymphoablation.

Original languageEnglish (US)
Pages (from-to)7260-7273
Number of pages14
JournalCancer Research
Volume74
Issue number24
DOIs
StatePublished - Dec 15 2014
Externally publishedYes

Fingerprint

Myxoma virus
Oncolytic Viruses
R Factors
Glioma
Virus Diseases
Cyclophosphamide
Natural Killer Cells
Therapeutics
Oncolytic Virotherapy
Macrophages
Ablation Techniques
T-Lymphocytes
Neoplasms
Microglia
Myeloid Cells
Knockout Mice
Cellular Immunity
Population
Monocytes
Immunity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Zemp, F. J., McKenzie, B. A., Lun, X., Reilly, K. M., McFadden, D., Yong, V. W., & Forsyth, P. A. (2014). Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. Cancer Research, 74(24), 7260-7273. https://doi.org/10.1158/0008-5472.CAN-14-0876

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. / Zemp, Franz J.; McKenzie, Brienne A.; Lun, Xueqing; Reilly, Karlyne M.; McFadden, Douglas; Yong, V. Wee; Forsyth, Peter A.

In: Cancer Research, Vol. 74, No. 24, 15.12.2014, p. 7260-7273.

Research output: Contribution to journalArticle

Zemp, Franz J. ; McKenzie, Brienne A. ; Lun, Xueqing ; Reilly, Karlyne M. ; McFadden, Douglas ; Yong, V. Wee ; Forsyth, Peter A. / Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. In: Cancer Research. 2014 ; Vol. 74, No. 24. pp. 7260-7273.
@article{8a36d541f64647b988a68c7740157ea8,
title = "Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus",
abstract = "Oncolytic virus therapy is being evaluated in clinical trials for human glioma. While it is widely assumed that the immune response of the patient to the virus infection limits the utility of the therapy, investigations into the specific cell type(s) involved in this response have been performed using nonspecific pharmacologic inhibitors or allogeneic models with compromised immunity. To identify the immune cells that participate in clearing an oncolytic infection in glioma, we used flow cytometry and immunohistochemistry to immunophenotype an orthotopic glioma model in immunocompetent mice after Myxoma virus (MYXV) administration. These studies revealed a large resident microglia and macrophage population in untreated tumors, and robust monocyte, T-, and NK cell in filtration 3 days after MYXV infection. To determine the role on the clinical utility of MYXV therapy for glioma, we used a combination of knockout mouse strains and specific immunocyte ablation techniques. Collectively, our experiments identify an important role for tumor-resident myeloid cells and overlapping roles for recruited NK and T cells in the clearance and efficacy of oncolytic MYXV from gliomas. Using a cyclophosphamide regimen to achieve lymphoablation prior and during MYXV treatment, we prevented treatment-induced peripheral immunocyte recruitment and, surprisingly, largely ablated the tumor-resident macrophage population. Virotherapy of cyclophosphamide-treated animals resulted in sustained viral infection within the glioma as well as a substantial survival advantage. This study demonstrates that resistance to MYXV virotherapy in syngeneic glioma models involves a multifaceted cellular immune response that can be overcome with cyclophosphamide-mediated lymphoablation.",
author = "Zemp, {Franz J.} and McKenzie, {Brienne A.} and Xueqing Lun and Reilly, {Karlyne M.} and Douglas McFadden and Yong, {V. Wee} and Forsyth, {Peter A.}",
year = "2014",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-14-0876",
language = "English (US)",
volume = "74",
pages = "7260--7273",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus

AU - Zemp, Franz J.

AU - McKenzie, Brienne A.

AU - Lun, Xueqing

AU - Reilly, Karlyne M.

AU - McFadden, Douglas

AU - Yong, V. Wee

AU - Forsyth, Peter A.

PY - 2014/12/15

Y1 - 2014/12/15

N2 - Oncolytic virus therapy is being evaluated in clinical trials for human glioma. While it is widely assumed that the immune response of the patient to the virus infection limits the utility of the therapy, investigations into the specific cell type(s) involved in this response have been performed using nonspecific pharmacologic inhibitors or allogeneic models with compromised immunity. To identify the immune cells that participate in clearing an oncolytic infection in glioma, we used flow cytometry and immunohistochemistry to immunophenotype an orthotopic glioma model in immunocompetent mice after Myxoma virus (MYXV) administration. These studies revealed a large resident microglia and macrophage population in untreated tumors, and robust monocyte, T-, and NK cell in filtration 3 days after MYXV infection. To determine the role on the clinical utility of MYXV therapy for glioma, we used a combination of knockout mouse strains and specific immunocyte ablation techniques. Collectively, our experiments identify an important role for tumor-resident myeloid cells and overlapping roles for recruited NK and T cells in the clearance and efficacy of oncolytic MYXV from gliomas. Using a cyclophosphamide regimen to achieve lymphoablation prior and during MYXV treatment, we prevented treatment-induced peripheral immunocyte recruitment and, surprisingly, largely ablated the tumor-resident macrophage population. Virotherapy of cyclophosphamide-treated animals resulted in sustained viral infection within the glioma as well as a substantial survival advantage. This study demonstrates that resistance to MYXV virotherapy in syngeneic glioma models involves a multifaceted cellular immune response that can be overcome with cyclophosphamide-mediated lymphoablation.

AB - Oncolytic virus therapy is being evaluated in clinical trials for human glioma. While it is widely assumed that the immune response of the patient to the virus infection limits the utility of the therapy, investigations into the specific cell type(s) involved in this response have been performed using nonspecific pharmacologic inhibitors or allogeneic models with compromised immunity. To identify the immune cells that participate in clearing an oncolytic infection in glioma, we used flow cytometry and immunohistochemistry to immunophenotype an orthotopic glioma model in immunocompetent mice after Myxoma virus (MYXV) administration. These studies revealed a large resident microglia and macrophage population in untreated tumors, and robust monocyte, T-, and NK cell in filtration 3 days after MYXV infection. To determine the role on the clinical utility of MYXV therapy for glioma, we used a combination of knockout mouse strains and specific immunocyte ablation techniques. Collectively, our experiments identify an important role for tumor-resident myeloid cells and overlapping roles for recruited NK and T cells in the clearance and efficacy of oncolytic MYXV from gliomas. Using a cyclophosphamide regimen to achieve lymphoablation prior and during MYXV treatment, we prevented treatment-induced peripheral immunocyte recruitment and, surprisingly, largely ablated the tumor-resident macrophage population. Virotherapy of cyclophosphamide-treated animals resulted in sustained viral infection within the glioma as well as a substantial survival advantage. This study demonstrates that resistance to MYXV virotherapy in syngeneic glioma models involves a multifaceted cellular immune response that can be overcome with cyclophosphamide-mediated lymphoablation.

UR - http://www.scopus.com/inward/record.url?scp=84917709275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84917709275&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-0876

DO - 10.1158/0008-5472.CAN-14-0876

M3 - Article

VL - 74

SP - 7260

EP - 7273

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -